Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Catalyst Pharm Inc
(NQ:
CPRX
)
21.24
+0.08 (+0.38%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Catalyst Pharm Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Why Groupon Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
May 11, 2023
Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) gained 109.8% to $1.06 after reporting a rise in Q1 sales.
Via
Benzinga
IBD 50 Leader And No. 1 Biotech Catalyst Puts Up 128% Earnings Growth
May 11, 2023
Though Catalyst's unadjusted earnings missed forecasts, they grew by triple digits.
Via
Investor's Business Daily
Catalyst Pharmaceuticals: Q1 Earnings Insights
May 10, 2023
Via
Benzinga
Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) is a Stock Spotlight on 4/11
April 11, 2023
Via
Investor Brand Network
1 Growth Stock to Buy Before the Next Bull Market
April 04, 2023
The stock is on a roll, and the company just made a major new purchase.
Via
The Motley Fool
Analyst Expectations for Catalyst Pharmaceuticals's Future
March 20, 2023
Via
Benzinga
Catalyst Pharmaceuticals Reports Record First Quarter 2023 Results, Achieving 98% Total Revenue Growth Year-over-Year
May 10, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals Advances sNDA Submission Plans To Increase Indicated Maximum Dose For FIRDAPSE® From 80 mg Per Day To 100 mg Per Day
May 09, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals Announces Release of Inaugural ESG Report
May 01, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
4 Analysts Have This to Say About Catalyst Pharmaceuticals
March 20, 2023
Via
Benzinga
Catalyst Pharmaceuticals Earnings Perspective: Return On Capital Employed
March 16, 2023
Via
Benzinga
Earnings Outlook For Catalyst Pharmaceuticals
March 14, 2023
Via
Benzinga
Catalyst Pharmaceuticals to Report First Quarter 2023 Financial Results on May 10, 2023
April 24, 2023
The Company Will Host a Conference Call and Webcast on May 11, 2023, at 8:30 AM ET
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharmaceuticals Announces Third-Party Abstracts on FYCOMPA® (Perampanel) to be Presented at the Upcoming American Academy of Neurology 2023 Annual Meeting
April 20, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
7 A-Rated Stocks to Buy for April 2023
April 07, 2023
Now that the first quarter's in the bank, here are seven A-rated stocks to buy for April to keep your portfolio in top-notch shape.
Via
InvestorPlace
2 Top Growth Stocks That Can Withstand an Economic Downturn
April 05, 2023
These two drugmakers should march higher in 2023 and beyond.
Via
The Motley Fool
Why Catalyst Pharmaceuticals Shares Are Moving
March 16, 2023
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) shares are trading higher by 9.66% to $15.72 Thursday morning after the company reported better-than-expected fourth-quarter results.
Via
Benzinga
Catalyst Pharma The No. 1 Biotech, Just Crushed 2023 Guidance Estimates
March 15, 2023
The guidance includes Catalyst's newest, and second, product.
Via
Investor's Business Daily
Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 15, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
7 Core Stocks to Build a Solid Portfolio Around
March 13, 2023
You’ll enjoy your investing journey more if you know that you can rely on your core of stocks to buy to provide a solid foundation.
Via
InvestorPlace
Earnings Scheduled For March 15, 2023
March 15, 2023
Companies Reporting Before The Bell • Sportradar Gr (NASDAQ:SRAD) is estimated to report quarterly earnings at $0.04 per share on revenue of $208.09 million.
Via
Benzinga
Catalyst Pharmaceuticals Announces a Recent Third-Party Publication in Peer-Reviewed Journal Epilepsia Showing Perampanel (FYCOMPA®) Demonstrated High Efficacy in Patients with Rare Genetic Epilepsies
March 08, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
2 Growth Stocks to Invest $1,000 in Right Now
March 03, 2023
Both of these biopharmas have major catalysts that are in play or drawing near.
Via
The Motley Fool
2 Breakout Growth Stocks to Buy for the Long Haul
March 03, 2023
These two stocks are entirely different, but they both make shareholders richer.
Via
The Motley Fool
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on March 15, 2023
March 01, 2023
The Company Will Host a Conference Call and Webcast on March 16, 2023, at 8:30 AM ET
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
7 Smart Stock Picks for Cautious Investors
February 28, 2023
As market volatility continues, consider playing it safe with these seven high-quality stocks for cautious investors.
Via
InvestorPlace
Catalyst Pharmaceuticals to Ring the Nasdaq Closing Bell in Honor of International Rare Disease Day
February 22, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
Catalyst Pharma Reveals Interim Q4 Earnings, Says Well Positioned For 2023
February 07, 2023
Via
Benzinga
Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2022 Total Revenues and Provides Full Year 2023 Revenue Guidance
February 07, 2023
From
Catalyst Pharmaceuticals, Inc.
Via
GlobeNewswire
The 7 Best Growth Stocks to Buy for February 2023
February 06, 2023
Some of the best growth stocks are lesser-known names that have the ability to provide tremendous long-term upside for investors.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.